

## Review Article

# Association between vitamin B<sub>12</sub> intake and EURRECA's prioritized biomarkers of vitamin B<sub>12</sub> in young populations: a systematic review

Iris Iglesia<sup>1,\*</sup>, Rosalie AM Dhonukshe-Rutten<sup>2</sup>, Silvia Bel-Serrat<sup>1</sup>, Esmée L Doets<sup>2</sup>, Adrienne EJM Cavelaars<sup>2</sup>, Pieter van 't Veer<sup>2</sup>, Mariela Nissenshohn<sup>3</sup>, Vassiliki Benetou<sup>4</sup>, María Hermoso<sup>5</sup>, Cristiana Berti<sup>6</sup>, Lisette CPGM de Groot<sup>2</sup> and Luis A Moreno<sup>1</sup>

<sup>1</sup>GENUD (Growth, Exercise, Nutrition and Development) Research Group, Health Sciences Faculty, Cervantes Building, C/ Corona de Aragón, n° 42, 2nd floor, 50009 University of Zaragoza, Zaragoza, Spain: <sup>2</sup>Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands: <sup>3</sup>Department of Clinical Sciences, Las Palmas de Gran Canaria University, Las Palmas de Gran Canaria, Spain: <sup>4</sup>Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece: <sup>5</sup>Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital, Ludwig Maximilians University of Munich Medical Centre, Munich, Germany: <sup>6</sup>Department of Clinical Sciences Hospital 'L Sacco' and Center for Fetal Research Giorgio Pardi, Unit of Obstetrics and Gynecology, University of Milan, Milan, Italy

Submitted 23 March 2012: Final revision received 3 July 2012: Accepted 17 July 2012: First published online 13 September 2012

### Abstract

**Objective:** To review evidence on the associations between vitamin B<sub>12</sub> intake and its biomarkers, vitamin B<sub>12</sub> intake and its functional health outcomes, and vitamin B<sub>12</sub> biomarkers and functional health outcomes.

**Design:** A systematic review was conducted by searching electronic databases, until January 2012, using a standardized strategy developed in the EURRECA network. Relevant articles were screened and sorted based on title and abstract, then based on full text, and finally included if they met inclusion criteria. A total of sixteen articles were included in the review.

**Setting:** Articles covered four continents: America (*n* 4), Europe (*n* 8), Africa (*n* 1) and Asia (*n* 3).

**Subjects:** Population groups included healthy infants, children and adolescents, and pregnant and lactating women.

**Results:** From the total number of 5815 papers retrieved from the initial search, only sixteen were eligible according to the inclusion criteria: five for infants, five for children and adolescents, and six for pregnant and lactating women.


**Conclusions:** Only one main conclusion could be extracted from this scarce number of references: a positive association between vitamin B<sub>12</sub> intake and serum vitamin B<sub>12</sub> in the infant group. Other associations were not reported in the eligible papers or the results were not provided in a consistent manner. The low number of papers that could be included in our systematic review is probably due to the attention that is currently given to research on vitamin B<sub>12</sub> in elderly people. Our observations in the current systematic review justify the idea of performing well-designed studies on vitamin B<sub>12</sub> in young populations.

**Keywords**  
Vitamin B<sub>12</sub>  
Intakes  
Biomarkers  
Young populations

Nutrition plays an important role in the programming of health across the lifespan, especially during the earliest periods, because of short- and long-term consequences in the absence of appropriate nutrition<sup>(1)</sup>. There are biological substances which keep homeostasis to prevent adverse health outcomes like vitamin B<sub>12</sub>. In recent years,

only a few studies have focused on the relationship between low vitamin B<sub>12</sub> intake and cognitive function, megaloblastic anaemia or growth in young populations.

Across Europe, current reference values for vitamin B<sub>12</sub> intake vary for infants from 0.3–0.5 to 1.5 µg/d depending on whether they are 3 or 9 months old, respectively<sup>(2)</sup>,



**Fig. 1** Intake–status–health relationships relevant for deriving reference values: 1 = intake–health relationship; 2 = intake–status relationship; 3 = status–health relationship

from 0.8 to 3.0  $\mu\text{g}/\text{d}$  for children and adolescents<sup>(3)</sup> and from 1.5 to 4.0  $\mu\text{g}/\text{d}$  for pregnant and lactating women<sup>(4,5)</sup>. The range of ages, values and terminology used for recommendations differ between European countries. However, the underlying concepts could be equivalent to: the RDA (Recommended Dietary Allowance, which is the daily dietary intake level of a nutrient considered sufficient to meet the requirements of nearly all (97–98%) healthy individuals in each life stage and gender group), the AI (Adequate Intake, which is an estimation of the lowest intake level that seems sufficient for almost all people in a group) and the acceptable range (which is defined as the range of intakes high enough to avoid deficiency and low enough to avoid toxic effects). For vulnerable population groups such as those represented herein, nutrient requirements are generally obtained from data extrapolated from the adult ANR (Average Nutrient Requirement, which is the estimated average or median requirement of a specific nutrient in a population)<sup>(6)</sup>.

In Western countries, the dietary intake of vitamin B<sub>12</sub> among children, adolescents and adults is usually higher than the average requirement for vitamin B<sub>12</sub>. For instance, the Spanish study EnKid showed that the 2–24-year-old population had a mean daily vitamin B<sub>12</sub> intake of 8.2  $\mu\text{g}$  (males) and 6.8  $\mu\text{g}$  (females)<sup>(7)</sup>. However, data from the Framingham Offspring Study suggest that suboptimal vitamin B<sub>12</sub> status occurs at intakes exceeding the recommended intakes<sup>(8)</sup> and raise the question of whether the current recommended intakes for vitamin B<sub>12</sub> are adequate to promote a normal vitamin B<sub>12</sub> status<sup>(9)</sup> and influence the occurrence of several health outcomes<sup>(8,10–12)</sup>.

The preferred approach to define the requirement takes into account the level of intake at which functioning is optimal. This implies that both preventing deficiencies as well as reducing the risk of developing other chronic disorders have to be taken into account<sup>(13,14)</sup>.

In order to provide up-to-date and evidence-based micronutrient reference values across Europe, it is important to assess the micronutrient status for different population groups<sup>(15)</sup> through its preferred biomarkers or functional health outcomes<sup>(16)</sup>. The use of a biomarker that reflects changes in micronutrient status can facilitate the understanding of the relationships between dietary micronutrient intake and status or health outcomes (Fig. 1). The best tools to provide this information are dose–response

and repletion–depletion studies, but they are rarely carried out.

The aim of the present paper is to systematically review dose–response evidence from randomized controlled trials (RCT), prospective cohort and cross-sectional studies on the association of vitamin B<sub>12</sub> with its main biomarkers, and also with its main health outcomes in infants, children, adolescents and pregnant and lactating women. The ultimate goal would be to provide micronutrient reference intake values for vitamin B<sub>12</sub> in the aforementioned population groups.

## Methods

The current systematic review on vitamin B<sub>12</sub> in young populations and pregnant and lactating women was performed within the framework of EURRECA ([www.eurreca.org](http://www.eurreca.org)) and has focused on one of the prioritized relationships set by the network<sup>(17)</sup> as illustrated in Fig. 1.

### Search methods for identification of studies

To find the search strategy terms and the criteria for exclusion/inclusion papers, data on vitamin B<sub>12</sub><sup>(17)</sup> were first reviewed. A multiple-database searching in MEDLINE, Embase (both on Ovid) and the Cochrane Library CENTRAL was carried out until 17 February 2009. The general search strategy included terms on study designs in humans AND (intake or status) AND (vitamin B<sub>12</sub>). The search terms included both MeSH terms and words to be found in the title or abstract. The initial search yielded 5815 references after exclusion of duplicates. Reference lists of six relevant review articles<sup>(18–23)</sup> were checked also to identify potentially relevant references that were not yet collected. This search did not yield any other references.

In January 2012 the search was repeated to retrieve other possible relevant papers. This search retrieved 596 new papers.

### Criteria for the consideration of studies

Studies had to fulfill the following criteria to be included in the review:

1. Investigate the possible relationships between vitamin B<sub>12</sub> intake, its biomarker levels or the selected health outcomes, following the structure available in Fig. 1;

2. Provide vitamin B<sub>12</sub> from supplements, fortified foods or natural dietary sources;
3. Be observational studies (prospective cohort, nested case-control or cross-sectional, the latter for intake-status associations only) or intervention studies (only RCT);
4. Be performed in human subjects from birth to 18 years or pregnant or lactating women;
5. Include apparently healthy subjects.

Results on adults and the elderly in studying these relationships are reported elsewhere.

Accepted dietary assessment methods to include the paper were: (i) validated FFQ/dietary history; and (ii) 24 h recall/food records/diary measures for at least 2 d.

Serum/plasma vitamin B<sub>12</sub>, methylmalonic acid (MMA) and holotranscobalamin (HoloTC)<sup>(24)</sup> were the biomarkers included as the most robust and sensitive biomarkers identified through earlier research activities in the EURRECA network<sup>(25,26)</sup>.

The health outcomes chosen were those most relevant for the population group (based on public health reports and the scientific literature, i.e. current evidence of a relationship and the number of preliminary search hits from online databases) and not recently and thoroughly covered by a similar review. Health outcomes differed between population groups:

1. Neurodevelopment and megaloblastic anaemia for infants;
2. Megaloblastic anaemia, growth and cognitive function for children and adolescents;
3. Fetal malformations and fetal growth for fetuses;
4. Megaloblastic anaemia and pre-eclampsia for mothers.

### Collection of papers

The results of the searches were combined in EndNote XII (Thompson Reuters). References were screened based on title and abstract. They were then sorted by population group: (i) infants, (ii) children and adolescents and (iii) pregnant and lactating women; and by relationship following the analytical model: (i) intake-health (I-H), (ii) intake-status (I-S), (iii) status-health (S-H) and (iv) intake-status-health (I-S-H).

### Selection of studies

Once papers were screened based on title and abstract and sorted by population group, those selected were again screened based on full text by obtaining them electronically, as photocopies or reprints, according to the pre-defined criteria. The reasons for exclusion and the name of the reviewer were registered in the EndNote library. One hundred and seventeen potentially relevant references were considered for inclusion based on full text review; characteristics of the 101 references excluded are shown in Table 1. Figure 2 shows the flowchart of the selection steps for the populations reviewed herein. If language expertise

existed in the review team, articles written in languages other than English could be included.

### Data extraction

Data from papers identified as relevant were extracted to characterize studies and to facilitate meta-analysis. Data were entered into an Access database specifically developed for EURRECA.

### Quality check controls

For alignment and quality control, at the start of each step two independent reviewers screened 10% of the references in duplicate. Any discrepancies at this step were discussed before proceeding with the rest of the references.

### Assessment of risk of bias in included studies

To exclude major sources of bias, internal validity of the relevant studies was assessed. The criteria used were adapted from the Cochrane Handbook<sup>(27)</sup>. The criteria for RCT were based on: method of sequence generation and allocation; blinding; potential funding bias; number of participants at start; drop-outs and reasons for dropping out; dose check; dietary intake data reported; and similarity of most and least exposed groups at baseline. For longitudinal studies the criteria were based on: drop-outs adequate and outcome data complete; funding; lack of other potential threats to validity; control for confounders; and assessment of exposure adequacy. For cross-sectional studies the criteria were based on: funding; lack of other potential threats to validity, such as those related to the specific study design used or related to differences in baseline characteristics of participants; confounders; and assessment of exposure adequacy.

## Results

The systematic search retrieved sixteen relevant papers. Table 2 summarizes the characteristics and results of these studies.

### Infants

Two out of five selected papers were RCT<sup>(28,29)</sup> and three were observational studies (one cross-sectional<sup>(30)</sup> and two longitudinal studies<sup>(31,32)</sup>). In all these studies the association between intake and status (I-S) was reported, except for one longitudinal study<sup>(32)</sup>. In both RCT, the intervention groups<sup>(28,29)</sup> received vitamin B<sub>12</sub> through intramuscular injection: once per month during the first 4 months (100 µg/month) in one study<sup>(29)</sup> and in the other<sup>(28)</sup> the injected amount was only once (400 µg). In the RCT from Worthington-White *et al.*<sup>(29)</sup>, serum levels were significantly increased after the intervention (either with or without folate supplementation) at each point of the measurements. In that study, the dose-response association between injected vitamin B<sub>12</sub> and levels of biomarkers was not estimated.

**Table 1** Characteristics of excluded studies

| Reference  | Main reason for exclusion   |
|--|---|
| Monsen <i>et al.</i> (2003) <sup>(58)</sup>          | Only data on biomarkers   |
| Monsen <i>et al.</i> (2006) <sup>(59)</sup>          | Does not address any relationships of interest                            |
| Casanueva <i>et al.</i> (2006) <sup>(60)</sup>       | Type of intervention: multivitamin supplement                             |
| Choudhry <i>et al.</i> (1972) <sup>(61)</sup>        | Study design: intervention but not RCT                                    |
| Cikot <i>et al.</i> (2001) <sup>(62)</sup>           | Only data on biomarkers   |
| Couto <i>et al.</i> (2007) <sup>(63)</sup>           | Only data on biomarkers   |
| Cornel <i>et al.</i> (2005) <sup>(64)</sup>          | Irrelevant micronutrient  |
| Czeizel and Dudas (1992) <sup>(65)</sup>             | Type of intervention: multi-vitamin supplement                            |
| Czeizel and Medveczky (2003) <sup>(66)</sup>         | Does not address any relationships of interest                            |
| Dagnelie <i>et al.</i> (1989) <sup>(67)</sup>        | Does not address any relationships of interest                            |
| Dawson <i>et al.</i> (2000) <sup>(68)</sup>          | Study design: intervention but not RCT                                    |
| van Dusseldorp <i>et al.</i> (1999) <sup>(69)</sup>  | Study design: case-control study  |
| Eilander <i>et al.</i> (2010) <sup>(70)</sup>        | Study design: cross-sectional study investigating S-H relationship        |
| Gomber <i>et al.</i> (2003) <sup>(71)</sup>          | Study design: cross-sectional study investigating S-H relationship        |
| Gomber <i>et al.</i> (1998) <sup>(72)</sup>          | Study design: cross-sectional study investigating S-H relationship        |
| Gordon and Carson (1976) <sup>(73)</sup>             | Study design: case report   |
| Graham <i>et al.</i> (1992) <sup>(74)</sup>          | Population group: infants did not meet the inclusion criteria (unhealthy) |
| Haggarty <i>et al.</i> (2006) <sup>(75)</sup>        | Irrelevant health outcome   |
| Haiden <i>et al.</i> (2006) <sup>(76)</sup>          | Type of intervention: multi-vitamin supplement                            |
| Haiden <i>et al.</i> (2006) <sup>(77)</sup>          | Type of intervention: multi-vitamin supplement                            |
| Hay <i>et al.</i> (2010) <sup>(78)</sup>             | Relationship assessed: S-S  |
| Hininger <i>et al.</i> (2004) <sup>(79)</sup>        | Type of intervention: multi-vitamin supplement                            |
| Hjelt and Krasilnikoff (1990) <sup>(80)</sup>        | Population group: infants did not meet the inclusion criteria (unhealthy) |
| Huemer <i>et al.</i> (2005) <sup>(81)</sup>          | Study design: case report   |
| Järvenpää <i>et al.</i> (2007) <sup>(82)</sup>       | Does not address any relationships of interest                            |
| Johnson <i>et al.</i> (2002) <sup>(83)</sup>         | Does not address any relationships of interest                            |
| Knight <i>et al.</i> (1994) <sup>(84)</sup>          | Only data on biomarkers   |
| Kuschel and Harding (2004) <sup>(19)</sup>           | Study design: systematic review   |
| Levy <i>et al.</i> (1992) <sup>(85)</sup>            | Type of intervention: multi-vitamin supplement                            |
| López de Romaña <i>et al.</i> (2005) <sup>(86)</sup> | Type of intervention: multi-vitamin supplement                            |
| Lovblad <i>et al.</i> (1997) <sup>(87)</sup>         | Irrelevant health outcome   |
| Lundgren and Blennow (1999) <sup>(88)</sup>          | Study design: case report   |
| Makedos <i>et al.</i> (2007) <sup>(89)</sup>         | Study design: case-control  |
| Mamluk <i>et al.</i> (1986) <sup>(90)</sup>          | Study design: case report   |
| Martin <i>et al.</i> (2004) <sup>(91)</sup>          | Does not address any relationships of interest                            |
| Mathan <i>et al.</i> (1979) <sup>(92)</sup>          | Does not address any relationships of interest                            |
| Mathews (1996) <sup>(20)</sup>                       | Does not address any relationships of interest                            |
| Maurage <i>et al.</i> (1995) <sup>(93)</sup>         | Does not address any relationships of interest                            |
| Masalha <i>et al.</i> (2008) <sup>(94)</sup>         | Study design: cross-sectional study investigating I-H relationship        |
| McCoy <i>et al.</i> (1984) <sup>(95)</sup>           | Only data on intakes  |
| McGrath <i>et al.</i> (2006) <sup>(96)</sup>         | Population group: mothers did not meet the inclusion criteria (unhealthy) |
| McNulty <i>et al.</i> (1996) <sup>(97)</sup>         | Only data on intakes  |
| Mena <i>et al.</i> (2001) <sup>(98)</sup>            | Irrelevant health outcome   |
| Meriardi <i>et al.</i> (2004) <sup>(99)</sup>        | Does not address any relationships of interest                            |
| Metcalf <i>et al.</i> (1994) <sup>(100)</sup>        | Does not address any relationships of interest                            |
| Metz <i>et al.</i> (1965) <sup>(101)</sup>           | Study design: intervention but not RCT                                    |
| Mills <i>et al.</i> (2005) <sup>(102)</sup>          | Type of intervention: multi-vitamin supplement                            |
| Minet <i>et al.</i> (2000) <sup>(103)</sup>          | Does not address any relationships of interest                            |
| Miyake <i>et al.</i> (2006) <sup>(104)</sup>         | Irrelevant health outcome   |
| Molloy <i>et al.</i> (1985) <sup>(105)</sup>         | Irrelevant health outcome   |
| Molloy <i>et al.</i> (2005) <sup>(106)</sup>         | Study design: cross-sectional study investigating S-H relationship        |
| Monagle and Tauro (1997) <sup>(107)</sup>            | Study design: description of several cases                                |
| Moran (2007) <sup>(108)</sup>                        | Only data on biomarkers   |
| Morkbak <i>et al.</i> (2007) <sup>(109)</sup>        | Study design: editor letter   |
| Msolla and Kinabo (1997) <sup>(110)</sup>            | Irrelevant biomarkers   |
| Murphy <i>et al.</i> (2007) <sup>(111)</sup>         | Study design: S-S   |
| Mwanda and Dave (1999) <sup>(112)</sup>              | Study design: intervention but not RCT                                    |
| Neiger <i>et al.</i> (1993) <sup>(113)</sup>         | Population group: mothers did not meet the inclusion criteria (unhealthy) |
| Nelen <i>et al.</i> (2000) <sup>(114)</sup>          | Does not address any relationships of interest                            |
| Neri <i>et al.</i> (2005) <sup>(115)</sup>           | Irrelevant health outcome   |
| Neuhouser <i>et al.</i> (1998) <sup>(116)</sup>      | Does not address any relationships of interest                            |
| Neumann and Harrison (1994) <sup>(117)</sup>         | Irrelevant health outcome   |
| Niebyl and Goodwin (2002) <sup>(118)</sup>           | Irrelevant health outcome   |
| Nikolaus and Nikolaus (1979) <sup>(119)</sup>        | Study design: intervention but not RCT                                    |
| Osganian <i>et al.</i> (1999) <sup>(120)</sup>       | Only data on biomarkers   |
| Patel and Lovelady (1998) <sup>(121)</sup>           | Study design: intervention but not RCT                                    |
| Ratan <i>et al.</i> (2008) <sup>(122)</sup>          | Does not address any relationships of interest                            |
| Ray and Laskin (1999) <sup>(23)</sup>                | Does not address any relationships of interest                            |

**Table 1** Continued

| Reference  | Main reason for exclusion   |
|--|---|
| Ray and Blom (2003) <sup>(53)</sup>                      | Irrelevant health outcome   |
| Ronnenberg <i>et al.</i> (2000) <sup>(123)</sup>         | Irrelevant population group   |
| Ronnenberg <i>et al.</i> (2002) <sup>(124)</sup>         | Irrelevant biomarkers   |
| Ronnenberg <i>et al.</i> (2002) <sup>(125)</sup>         | Study design: case-control  |
| Ronnenberg <i>et al.</i> (2007) <sup>(126)</sup>         | Does not address any relationships of interest  |
| Rumbold <i>et al.</i> (2005) <sup>(127)</sup>            | Type of intervention: multi-vitamin supplement  |
| Sachdeva and Mann (1994) <sup>(128)</sup>                | Does not address any relationships of interest  |
| Scatliff <i>et al.</i> (2011) <sup>(129)</sup>           | Population group: children did not meet the inclusion criteria (unhealthy)                        |
| Schneede <i>et al.</i> (1994) <sup>(130)</sup>           | Only data on biomarkers   |
| Shih <i>et al.</i> (1976) <sup>(131)</sup>               | Study design: editor letter   |
| Siekman <i>et al.</i> (2003) <sup>(132)</sup>            | The intervention was realized with meat or milk   |
| Singla <i>et al.</i> (1982) <sup>(133)</sup>             | Type of intervention: multi-vitamin supplement  |
| Sivakumar <i>et al.</i> (2006) <sup>(134)</sup>          | Only data on biomarkers   |
| Smith Fawzi <i>et al.</i> (2007) <sup>(135)</sup>        | Irrelevant health outcome   |
| Sneed <i>et al.</i> (1981) <sup>(136)</sup>              | Study design: intervention but not RCT  |
| Sohrabvand <i>et al.</i> (2006) <sup>(137)</sup>         | Irrelevant health outcome   |
| Stegers-Theunissen <i>et al.</i> (1995) <sup>(138)</sup> | Does not address any relationships of interest  |
| Steen <i>et al.</i> (1998) <sup>(139)</sup>              | Irrelevant health outcome   |
| Strand <i>et al.</i> (2007) <sup>(140)</sup>             | Does not address any relationships of interest  |
| Suarez <i>et al.</i> (2003) <sup>(141)</sup>             | Irrelevant health outcome   |
| Thomas <i>et al.</i> (2008) <sup>(142)</sup>             | Does not address any relationships of interest  |
| Thompson <i>et al.</i> (2009) <sup>(143)</sup>           | Irrelevant health outcome   |
| Thoradeniya <i>et al.</i> (2006) <sup>(144)</sup>        | Only data on biomarkers   |
| Thurlow <i>et al.</i> (2005) <sup>(145)</sup>            | Study design: cross-sectional study investigating S-H relationship                                |
| Valman (1972) <sup>(146)</sup>                           | Study design: case report   |
| Veena <i>et al.</i> (2010) <sup>(147)</sup>              | Study design: maternal S and children's H at 10 years old   |
| Verkleij-Hagoort <i>et al.</i> (2008) <sup>(148)</sup>   | Study design: case-control  |
| Villamor <i>et al.</i> (2008) <sup>(149)</sup>           | Study design: data from I is referred to dietary patterns, not to proper amounts of micronutrient |
| Vinod Kumar and Rajagopalan (2008) <sup>(150)</sup>      | Type of intervention: multi-vitamin supplement  |
| Vujkovic <i>et al.</i> (2007) <sup>(151)</sup>           | Study design: data from I is referred to dietary patterns, not to proper amounts of micronutrient |
| Vujkovic <i>et al.</i> (2009) <sup>(152)</sup>           | Study design: data from I is referred to dietary patterns, not to proper amounts of micronutrient |
| Wald <i>et al.</i> (1996) <sup>(153)</sup>               | Irrelevant health outcome   |
| Wright (1995) <sup>(154)</sup>                           | Study design: case-control  |

RCT, randomized controlled trial; S, status; H, health; I, intake.


In the RCT from Bjorke-Monsen *et al.*<sup>(28)</sup>, the intervention was the strongest predictor of changes for all blood indices (regression coefficient = 183 for serum vitamin B<sub>12</sub> and regression coefficient = -0.70 for MMA). Four months after delivery, the median (range) of serum vitamin B<sub>12</sub> was 421 (291-497) pmol/l and 240 (162-337) pmol/l for the intervention and placebo groups, respectively; corresponding values for MMA were 0.2 (0.15-0.43) pmol/l and 0.51 (0.23-1.55) pmol/l.

In the Guatemalan cross-sectional study<sup>(30)</sup>, mean intake of vitamin B<sub>12</sub> was 3.1 µg/d for mothers and 2.2 µg/d for infants at the age of 12 months and the accompanying mean (SD) plasma vitamin B<sub>12</sub> concentration in mothers and infants was 114.4 (9.2) g/l and 262.2 (163.5) pmol/l, respectively. The plasma vitamin B<sub>12</sub> concentrations of the infants were correlated with maternal concentrations and they were also positively associated with infant B<sub>12</sub> intake from complementary foods ( $r = 0.16$ ,  $P < 0.0001$ ).

In the longitudinal study by Hay *et al.*<sup>(31)</sup>, the results were divided between breast-fed ( $n = 104$ ) and non-breast-fed ( $n = 115$ ) infants: the mean intake of vitamin B<sub>12</sub> was 1.4 (95% CI 1.3, 1.6) µg/d for breast-fed infants excluding the

intake from breast milk and 2.4 (95% CI 2.1, 2.6) µg/d for the non-breast-fed infants. In that study, the selected biomarkers were measured at the age of 12 months. Mean (95% CI) serum vitamin B<sub>12</sub>, HoloTC and MMA were 343 (319, 369) pmol/l, 54 (49, 60) pmol/l and 0.22 (0.20, 0.25) µmol/l, respectively, for breast-fed infants, and 397 (372, 424) pmol/l, 76 (70, 83) pmol/l and 0.20 (0.19, 0.22) µmol/l, respectively, for non-breast-fed infants. Infants who were breast-fed at the age of 12 months had significantly lower serum vitamin B<sub>12</sub> and HoloTC and higher MMA than those who were not breast-fed at the same age. In that study, total vitamin B<sub>12</sub> intake from complementary foods was positively associated with serum vitamin B<sub>12</sub> ( $r = 0.15$  and  $P = 0.030$ ) and HoloTC ( $r = 0.25$  and  $P = 0.001$ ).

The longitudinal study by Dagnelie *et al.*<sup>(32)</sup> was the only one studying the relationship between vitamin B<sub>12</sub> intake and health, specifically psychomotor development, in spite of the status also being stated in the paper. However, they were not related with intakes or health outcomes. The results were divided between infants following a specified macrobiotic diet and those following an omnivorous one.



**Fig. 2** Selection of studies for the current systematic review

Mean vitamin B<sub>12</sub> intakes were significantly higher in the omnivorous group (2.9 (SD 1.3) µg/d) in comparison to the macrobiotic group (0.3 (SD 0.2) µg/d;  $P < 0.001$ ). These differences could also be shown in the scores obtained in the psychomotor development test in the areas of gross motor development (for which the mean difference in standard deviations between feeding groups was  $-0.48$ ) and speech and language development (for which the mean difference in standard deviations between feeding groups was  $-0.42$ ), with a  $P$  value of 0.04 and 0.03, respectively. Despite these differences in health outcomes obtained between feeding groups, the authors did not study an association between vitamin B<sub>12</sub> intakes and differences in scores in psychomotor tests; for this reason, these results cannot be attributed only to the obtained difference in vitamin B<sub>12</sub> intakes.

The results of the four studies evaluating the I-S relationship showed that the status of vitamin B<sub>12</sub> biomarkers is significantly and positively associated with vitamin B<sub>12</sub>

consumption (ingested or injected). The strength of this association was stated in almost all of the studies, with the exception of one RCT<sup>(29)</sup> in which the regression coefficient was not given. The limited availability of I-H data in infants did not allow for drawing any conclusions.

#### **Children and adolescents**

For the children and adolescents group, we identified four cross-sectional studies<sup>(33–35,37)</sup> and one RCT<sup>(36)</sup>. Two out of three cross-sectional studies were conducted with children<sup>(33,37)</sup>, one study<sup>(34)</sup> was carried out among adolescents and one<sup>(35)</sup> included both children and adolescents. In three cross-sectional studies<sup>(33–35)</sup>, vitamin B<sub>12</sub> intake and plasma vitamin B<sub>12</sub> was described. However, searching for an association between intake and status was not the purpose of the studies. Only in the study by Hay *et al.*<sup>(37)</sup>, performed in Norwegian children, was vitamin B<sub>12</sub> intake shown to be significantly and positively associated ( $r = 0.21$ ,  $P < 0.05$ ) with HoloTC. In that study, serum

**Table 2** Main characteristics of the studies selected in the systematic review by study population group

| Group  | Study  | Country   | Population (characteristics, n)   | Objectives  | Design  | Intake  | Status   | Health outcome   | Results  | Conclusion   |
|--|--|---|---|---|---|---|--|--|--|--|
| Infants  | Dagnelie and van Staveren (1994) <sup>(32)</sup>       | Netherlands                                       | 4–18-month-years old macrobiotic infants (n 53) and omnivorous control subjects (n 57) were assessed in three cohorts: one cohort aged 4–10 months, the second cohort aged 8–14 months and the third cohort aged 12–18 months | To associate macrobiotic diets in infants with lower scores in psychomotor development in comparison with omnivorous diet infants | Population-based, mixed-longitudinal cohort study, in which omnivorous group was frequency-matched with the macrobiotic group for month of birth, sex, parity, education of the parents and region of residence | Mean (sd) vitamin B <sub>12</sub> intake (μg/d) was significantly different in the macrobiotic group (n 49), 0·3 (sd 0·2), and the omnivorous group (n 57), 2·9 (sd 1·3), P < 0·001   | Plasma vitamin B <sub>12</sub> concentrations were 149 pmol/l in macrobiotic infants and 404 pmol/l in omnivorous infants (P < 0·001)  | Differences in psychomotor development of macrobiotic infants relative to omnivorous infants (means of differences in sd): –0·48 for gross motor development and –0·42 for speech and language development     | The psychomotor checklist revealed that the macrobiotic group was significantly slower in gross motor (P = 0·04) and in speech and language development (P = 0·03) | The macrobiotic group had worst scores regarding psychomotor development. However, no association with lower intakes of vitamin B <sub>12</sub> was looked for   |
|  | Worthington-White <i>et al.</i> (1994) <sup>(32)</sup> | USA   | 184 premature infants (< 1800 g at birth and < 36 weeks' gestation)   | To investigate if IM injection of vitamin B <sub>12</sub> has effects on vitamin B <sub>12</sub> biomarkers                       | Single-centre, randomized, placebo-controlled trial. Study groups: folate + vitamin B <sub>12</sub> supplementation; folate only; vitamin B <sub>12</sub> only; and no additional supplementation               | Control group: vitamin B <sub>12</sub> 15 μg/l/d administered IM + 0·07 pmol/l administered by formula fed as tolerated. Supplemented group: the same as control group + 100 μg vitamin B <sub>12</sub> IM per month for 4 months | Mean (SEM) serum vitamin B <sub>12</sub> (pmol/l) in supplemented groups <sup>(29)</sup> was 640 (100) at baseline, 1150 (130)* at 1–2 weeks, 990 (110)* at 3–4 weeks, 830 (100)† at 6–8 weeks, 910 (150)† at 10–12 weeks and 1010 (230)† at 6 months. In the control group <sup>(28)</sup> the corresponding amounts were: 830 (200), 640 (60)†, 500 (60)*, 270 (50)†, 380 (60)† and 810 (180). *†‡Significantly different from values at birth: *P < 0·01; †P < 0·05; ‡P < 0·005 | Not stated   | Not stated   | In vitamin B <sub>12</sub> -supplemented patients, an increase in serum B <sub>12</sub> concentrations was serologically demonstrated in comparison with those who did not receive any supplementation |
|  | Jones <i>et al.</i> (2007) <sup>(30)</sup>             | Guatemala   | 304 infants and their mothers   | To examine predictors of deficient plasma vitamin B <sub>12</sub> concentrations  | Cross-sectional study. A door-to-door census was conducted and SES, anthropometry, dietary intake of vitamin B <sub>12</sub> and micronutrient status were measured at 12 months of age                         | Estimated mean intake of vitamin B <sub>12</sub> in mothers was 3·1 μg/d and 2·2 μg/d in infants using a semi-quantitative FFQ  | Mean (sd) plasma vitamin B <sub>12</sub> in infants was 262·2 (163·5) pmol/l and in mothers 114·4 (9·2) g/l  | Not stated   | Infant intake of B <sub>12</sub> is a predictor of infant plasma B <sub>12</sub> (r = 0·16, P < 0·0001; n 270)   | Infant intake from complementary foods was positively associated with infant plasma vitamin B <sub>12</sub>  |
| Bjorke-Monsen <i>et al.</i> (2008) <sup>(28)</sup> | Norway   | 107 healthy, term, 6-week-old (± 2 weeks) infants | To investigate if IM injection of vitamin B <sub>12</sub> has effects on vitamin B <sub>12</sub> biomarkers   | RCT. Intervention group: n 54; control group: n 53  | An IM injection of 400 μg of hydroxycobalamin after blood sampling at the first visit   | In the intervention group, median (range) serum B <sub>12</sub> (pmol/l) was 172 (128–250) at 6 weeks and 421 (291–497) at 4 months; median (range) MMA (pmol/l) was 0·58 (0·28–0·97) at 6 weeks and 0·20 (0·15–0·43) at 4 months | Not stated   | Regression coefficient = 183 (P < 0·001) for serum vitamin B <sub>12</sub> and regression coefficient = –0·70 (P < 0·001) for MMA, between injected vitamin B <sub>12</sub> and vitamin B <sub>12</sub> status | At 4 months, vitamin B <sub>12</sub> intervention was by far the strongest predictor of infant vitamin B <sub>12</sub> status                                      |  |

Table 2 Continued

| Group                    | Study  | Country | Population (characteristics, n)  | Objectives   | Design  | Intake  | Status   | Health outcome   | Results  | Conclusion   |
|--------------------------|--|---------|--|--|---|---|--|--|--|--|
|                          | Hay <i>et al.</i> (2008) <sup>(31)</sup>         | Norway  | 364 mothers and their healthy children   | To investigate if different levels of intake of vitamin B <sub>12</sub> have effects on vitamin B <sub>12</sub> biomarkers | In a longitudinal study, serum vitamin B <sub>12</sub> , HoloTC and MMA were measured at birth and at 6, 9, 12, 18 and 24 months  | Mean (95% CI) daily intake of vitamin B <sub>12</sub> at 12 months, excluding intake from breast milk, in breast-fed ( <i>n</i> 104) and non-breast-fed ( <i>n</i> 115) infants was 1.4 (1.3, 1.6) µg and 2.4 (2.1, 2.6) µg, respectively ( <i>P</i> < 0.001), measured by using questionnaires and 7 d weighed-food records at 12 months | Mean (95% CI) serum vitamin B <sub>12</sub> , HoloTC and MMA (pmol/l) were 343 (319, 369; <i>n</i> 85), 54 (49, 60; <i>n</i> 78) and 0.22 (0.20, 0.25; <i>n</i> 86), respectively, for breast-feeding infants receiving complementary foods. Corresponding values were 397 (372, 424; <i>n</i> 127), 76 (70, 83; <i>n</i> 117) and 0.20 (0.19, 0.22; <i>n</i> 125) for non-breast-fed infants at 12 months | Not stated   | Partial <i>r</i> values considering total vitamin B <sub>12</sub> intake were 0.15 ( <i>P</i> = 0.030) for serum vitamin B <sub>12</sub> and 0.25 ( <i>P</i> = 0.001) for HoloTC | Vitamin B <sub>12</sub> intake at 12 months was significantly associated with both serum vitamin B <sub>12</sub> and HoloTC  |
| Children and adolescents | Papoutsakis <i>et al.</i> (2006) <sup>(33)</sup> | Greece  | 186 sixth-grade students (99 females and 87 males aged 10.8–13.5 years)  | To describe the intake and the status of vitamin B <sub>12</sub> in children   | Cross-sectional study by face-to-face interview. B <sub>12</sub> was measured in plasma and dietary intake data were collected by two non-consecutive 24 h recalls  | Mean (95% CI) for vitamin B <sub>12</sub> intake was 3.2 (2.7, 3.8) µg/d in females and 3.7 (3.1, 4.5) µg/d in males ( <i>P</i> = 0.024)  | Mean (95% CI) for plasma vitamin B <sub>12</sub> (pmol/l) was 411 (388, 435) for females ( <i>n</i> 99) and 383 (360, 406) for males ( <i>n</i> 87)  | Not stated   | Not stated   | Not stated   |
|                          | Gewa <i>et al.</i> (2009) <sup>(36)</sup>        | Kenya   | 520 children (270 boys and 250 girls) with a mean age of 7.4 years, belonging to twelve selected schools randomized to one of four feeding groups during 24 months | To evaluate the relationship between dietary vitamin B <sub>12</sub> and gains in cognitive test scores                    | A 2-year longitudinal, randomized controlled feeding intervention study using animal-source foods, in which dietary nutrient values were obtained from nineteen 24 h recalls (at least once per month), and a cognitive battery test repeated once per term | As there were no significant differences between boys and girls regarding vitamin B <sub>12</sub> intakes, mean intake for the entire group was 0.64 (sd 0.38) µg   | Not stated   | As there were no significant differences between boys and girls regarding Digit span-forward test, mean (sd) score in this part of the cognitive test for the entire group was 2.79 (1.12) | A child with a daily high intake of vitamin B <sub>12</sub> gained a significant 0.24 more points in the Digit Span-forward test than one with a low intake level                | These results demonstrate the importance of improved intake of vitamin B <sub>12</sub> contained in animal-source foods on cognitive function among school-aged children |
|                          | Hay <i>et al.</i> (2011) <sup>(37)</sup>         | Norway  | 178 children from 2-year-olds (68 girls and 87 boys)   | To examine vitamin B <sub>12</sub> intake in relation to serum vitamin B <sub>12</sub> status in 2-year-olds               | Cross-sectional study by face-to-face interview. B <sub>12</sub> was measured in plasma and dietary intake data were collected by 7 d weighed records (seven consecutive days). Information on supplement use was also taken                                | Mean vitamin B <sub>12</sub> intake without gender differences was 3.1 µg/d   | Median serum vitamin B <sub>12</sub> was 407 pmol/l for the total population, median HoloTC was 93 and 106 pmol/l for boys and girls, and MMA was 0.16 and 0.14 µmol/l for boys and girls, respectively (significant differences between boys and girls for HoloTC and MMA; <i>n</i> 155)  | Not stated   | Significant correlation was found for vitamin B <sub>12</sub> intake and HoloTC ( <i>r</i> = 0.21, <i>P</i> < 0.05)  | HoloTC was more significantly associated with vitamin B <sub>12</sub> intake than other biomarkers   |



Table 2 Continued

| Group                        | Study   | Country  | Population (characteristics, n)   | Objectives  | Design  | Intake   | Status  | Health outcome   | Results  | Conclusion  |
|------------------------------|---|----------|---|---|---|--|---|--|--|---|
|                              | Steluti <i>et al.</i> (2011) <sup>(34)</sup>  | Brazil   | 99 adolescents (58.6% were girls) whose mean age was 17.6 years                                 | To report vitamin B <sub>12</sub> intakes and serum concentrations in Brazilian adolescents   | Cross-sectional study by face-to-face interview. B <sub>12</sub> was measured in plasma and dietary intake data were collected by 3 d records (three non-consecutive days)  | Mean (95% CI) vitamin B <sub>12</sub> intake was 4.45 (4.28, 4.64) µg/d                              | Mean (sd) serum vitamin B <sub>12</sub> was 397.5 (188.4) pg/ml   | Not stated   | Not stated   | Not stated  |
|                              | Yeung <i>et al.</i> (2011) <sup>(35)</sup>    | USA      | Non-pregnant population aged 1–18 years (n 7161)  | To report vitamin B <sub>12</sub> intakes and serum concentrations in US children and adolescents   | Cross-sectional study. B <sub>12</sub> was measured in plasma and dietary intake data by two 24 h recalls on non-consecutive days (the first in person and the second by telephone). Information on supplement use was also taken | Results are shown by FA consumption group and sociodemographic characteristics                       | Mean serum vitamin B <sub>12</sub> (n 5895) and MMA (n 2436) results are shown by FA consumption group and sociodemographic characteristics   | Not stated   | Not stated   | Not stated  |
| Pregnant and lactating women | Koebnick <i>et al.</i> (2002) <sup>(39)</sup> | Germany  | 39 healthy pregnant women participated in the study throughout their pregnancies until delivery | To describe ranges of biochemical indices of vitamin B <sub>12</sub> status and vitamin B <sub>12</sub> intake in all trimesters of uncomplicated pregnancy | Prospective longitudinal study in which serum vitamin B <sub>12</sub> and dietary intake data (using 4 d food records) were assessed in weeks 9–12, 20–22 and 36–38. Intake of supplements was recorded                           | Mean (sd) intake of vitamin B <sub>12</sub> from the first to the third trimester was 5.6 (2.0) µg/d | Mean (95% CI) serum B <sub>12</sub> (pmol/l): 257 (226–292) in 1st month <sup>(31)</sup> , 239 (212–268) in 2nd month <sup>(39)</sup> and 178 (161–198) in 3rd month <sup>(38)</sup> , with $P < 0.0001$ adjusted for maternal age  | Not stated   | Not stated   | The intake of vitamin B <sub>12</sub> did not correlate with vitamin B <sub>12</sub> concentrations in blood  |
|                              | Lindblad <i>et al.</i> (2005) <sup>(40)</sup> | Pakistan | 46 women and their IUGR infants as well as 82 pairs with normal birth weight                    | To investigate whether IUGR was associated with altered maternal and fetal levels of vitamin B <sub>12</sub>  | Prospective observational study. Mothers and fetuses were followed at least 3–4 times since week 12 of pregnancy until the delivery   | Not stated   | Median (range) serum vitamin B <sub>12</sub> (pmol/l) in mothers: IUGR 96 (23–266), normal 108 (29–317). Median (range) vitamin B <sub>12</sub> (pmol/l) in umbilical cord: IUGR 190 (61–913), normal 171 (48–534). Median (range) maternal vitamin B <sub>12</sub> was 102 (23–317) pmol/l | 46 infants were considered IUGR v. 82 who had normal birth weight. 21% of normal birth weight infants' mothers had pre-eclampsia and 26% of IUGR mothers | $P$ values for maternal ( $P = 0.42$ ) or umbilical cord ( $P = 0.24$ ) vitamin B <sub>12</sub> levels (pmol/l) in comparison between IUGR and normal birth weight. Birth weight was not significantly different between mothers with pre-eclampsia ( $P = 0.53$ ) | Neither maternal nor umbilical cord vitamin B <sub>12</sub> levels were associated with IUGR. There were no significant differences between IUGR and normal birth weight infants' mothers regarding pre-eclampsia |

Table 2 Continued

| Group | Study   | Country | Population (characteristics, <i>n</i> )   | Objectives   | Design  | Intake  | Status  | Health outcome   | Results   | Conclusion  |
|-------|---|---------|---|--|---|---|---|--|---|---|
|       | Muthayya <i>et al.</i> (2006) <sup>(42)</sup> | India   | 478 pregnant women were recruited at 12.9±3.3 weeks' gestation  | To assess maternal dietary vitamin B <sub>12</sub> and its biomarkers in apparently healthy pregnant women in order to determine their associations with IUGR        | Prospective cohort study. Information on sociodemographic factors at baseline and on maternal anthropometry, dietary intake, clinical status and blood at baseline, second trimester of pregnancy and third trimester of pregnancy were collected | An FFQ for the preceding 3 months of each trimester, validated against 24 h recalls obtained thrice for each trimester, was assessed for each pregnant woman. Mean intakes of vitamin B <sub>12</sub> were not stated | In a subsample of 185 women, serum vitamin B <sub>12</sub> medians and IQR for each trimester and for each tertile were obtained  | The incidence of IUGR babies was 28.6% ( <i>n</i> 108) | AOR = 5.98, 9.28 and 2.81 in trimesters 1 to 3, respectively, for women in the lowest tertile for serum B <sub>12</sub> concentration during each of the trimesters of pregnancy in relation to risk of IUGR. Coefficients of correlation between vitamin B <sub>12</sub> intake and status in all three trimesters: trimester 1 ( <i>n</i> 135, <i>r</i> = 0.22, <i>P</i> = 0.009); trimester 2 ( <i>n</i> 140, <i>r</i> = 0.21, <i>P</i> = 0.013); trimester 3 ( <i>n</i> 147, <i>r</i> = 0.20, <i>P</i> = 0.017) | Women in the lowest tertile for serum B <sub>12</sub> concentration during each of the trimesters of pregnancy had significantly higher risk of IUGR                |
|       | Morkbak <i>et al.</i> (2007) <sup>(41)</sup>  | Denmark | Apparently healthy lactating mothers ( <i>n</i> 89) including 23 supplemented with vitamin B <sub>12</sub> , 41 partly supplemented and 25 not supplemented | To examine longitudinal changes in serum cobalamins during lactation and to investigate the influence of vitamin B <sub>12</sub> supplementation on these parameters | A 9-month follow-up study for three different statuses of supplementation pregnant groups. Blood samples collected week 3 (baseline) and months 4 and 9 postpartum were analysed for cobalamins   | Median (range) of B <sub>12</sub> supplementation (µg/d): 1 (0–13.5) at baseline ( <i>n</i> 89); 1 (0–13.5) at 4 months ( <i>n</i> 87); 0 (0–18.0) at 9 months ( <i>n</i> 86)   | Median (range) cobalamins (pmol/l): 322 (129–1039) at baseline ( <i>n</i> 89); 317 (114–1247) at 4 months ( <i>n</i> 87); 315 (145–1193) at 9 months ( <i>n</i> 86). Median (range) HoloTC (pmol/l): 85 (30–1068) at baseline ( <i>n</i> 89); 87 (20–1020) at 4 months ( <i>n</i> 87); 76 (30–972) at 9 months ( <i>n</i> 86) | Not stated   | <i>P</i> values for differences in cobalamin status between baseline and 4 months and between 4 months and 9 months were not statistically significant; <i>P</i> = 0.02 between baseline and 4 months and <i>P</i> = 0.01 between 4 and 9 months for HoloTC   | The levels of serum cobalamins and HoloTC after 9 months showed no statistical differences between the groups supplemented or unsupplemented at any of three visits |
|       | Baker <i>et al.</i> (2009) <sup>(38)</sup>    | UK      | 500 pregnant adolescents (14–18 years) were recruited from 2 inner-city populations at gestational age ≤20 weeks  | To assess vitamin B <sub>12</sub> intake and its biomarkers in pregnant women and to determine associations with infant growth                                       | Prospective study. Three non-consecutive 24 h recalls were conducted during the third trimester. Supplement use was also recorded   | Mean (SD) intake of vitamin B <sub>12</sub> of 290 mothers was 5.31 (4.96) µg/d; median (IQR) was 4.31 (2.97–6.11) µg/d   | In 290 mothers, mean (95% CI) serum vitamin B <sub>12</sub> (pmol/l) of SGA infants ( <i>n</i> 45) was 188 (166–212) and 175 (167–184) for non-SGA ( <i>n</i> 245)  | 17.6% were SGA ( <i>n</i> 478)                         | Ratios of geometric means between SGA and non-SGA births were 1.07 (0.94–1.22) with <i>P</i> = 0.276 by simple regression analysis and 1.10 (0.98–1.23) with <i>P</i> = 0.092 by multiple regression analysis   | Serum vitamin B <sub>12</sub> in mothers was not associated with SGA infants  |

Table 2 Continued

| Group | Study   | Country | Population (characteristics, n)  | Objectives  | Design            | Intake         | Status   | Health outcome  | Results  | Conclusion  |
|-------|---|---------|--|---|-------------------|----------------|--|---|--|---|
|       | Takimoto <i>et al.</i> (2011) <sup>(43)</sup> | Japan   | 33 healthy pregnant women at the third trimester, 14 FA users (33.1 (sd 5) years) and 19 non-FA users (32.7 (sd 4.1) years), were recruited in obstetric department in central Tokyo | To describe biochemical indices of maternal vitamin B <sub>12</sub> status and fetal growth | Prospective study | Not applicable | Mean (sd) maternal vitamin B <sub>12</sub> (pg/ml) in the third trimester of FA users was 193.8 (68.8) and in non-users was 218.6 (62.2). Mean (sd) maternal vitamin B <sub>12</sub> (pg/ml) at 1 month after birth of FA users was 355.8 (143.7) and in non-users was 391.2 (141.8) | Mean (sd) gestational length (weeks) was 39.3 (1.2) in FA users and 40.2 (1.1) in non-users. In girls, mean (sd) head circumference (cm) was 32.0 (1.5) in FA users and 33.9 (1.9) in non-users. In boys, mean (sd) birth weight (g) was 2908 (305) in FA users and 3195 (260) in non-users | Statistically significant differences were found between infants from FA users and non-users regarding gestational length (total group), head circumference (only girls) and weight (only boys). Blood vitamin B <sub>12</sub> was not associated with infants' anthropometric characteristics | Maternal vitamin B <sub>12</sub> status was not associated with gestational weight, weight, length or head circumference of infants at delivery or 1 month after delivery |

IUGR, intra-uterine growth retardation; FA, folic acid supplement intake; IM, intramuscular (ly); SES, socio-economic status; RCT, randomized controlled trial; HoloTC, holotranscobalamin; MMA, methylmalonic acid; IQR, interquartile range; SEM, standard error of measurement; SGA, small-for-gestational age; AOR, adjusted odds ratio.

vitamin B<sub>12</sub> and MMA were also measured; however, no association with them was found.

In the RCT by Gewa *et al.*<sup>(36)</sup>, the targeted population group was children and the studied relationship was I-H. The authors discovered that children with a daily high intake of vitamin B<sub>12</sub> gained a significant 0.24 more points in the Digit Span-forward test (as part of the entire cognitive test) than others with a low intake level, considering intakes of vitamin B<sub>12</sub> predictors of the Digit Span-forward test.

**Pregnant and lactating women**

Regarding the pregnant and lactating women group, six prospective observational studies were included<sup>(38-43)</sup>. Four of them studied the relationship between status and health outcomes in the fetus (intra-uterine growth retardation (IUGR), small for gestational age (SGA) and growth in general)<sup>(38,40,42,43)</sup>. In Lindblad *et al.*'s study<sup>(40)</sup>, the results suggested that in infants with normal birth weight, cord blood levels of vitamin B<sub>12</sub> were correlated with maternal levels of serum vitamin B<sub>12</sub>. However these correlations were weaker when infants had IUGR. In the study by Baker *et al.*<sup>(38)</sup>, serum vitamin B<sub>12</sub> levels in mothers were not associated with the risk of SGA infants. However, in Muthayya *et al.*'s study<sup>(42)</sup> women in the lowest tertile for serum vitamin B<sub>12</sub> concentration during each of the trimesters of pregnancy had significantly higher risk of delivering IUGR infants. In this last study, a correlation between vitamin B<sub>12</sub> intake and status was also reported in all three trimesters. In Takimoto *et al.*'s study<sup>(43)</sup>, maternal vitamin B<sub>12</sub> status, assessed in the third trimester of the pregnancy, was not associated with gestational weight, weight, length or head circumference of infants at delivery or at 1 month after delivery. Two studies<sup>(39,41)</sup> described longitudinal changes in vitamin B<sub>12</sub> biomarkers through pregnancy, I-S being the main relationship examined. In one longitudinal study<sup>(39)</sup>, vitamin B<sub>12</sub> intake in pregnant women was not associated with serum vitamin B<sub>12</sub>. In the study by Morkbak *et al.*<sup>(41)</sup>, which is the only selected study on pregnant women, in spite of there being three different supplementation groups, as there were no significant differences between them, results were presented for all three groups together. No change was observed in serum vitamin B<sub>12</sub> throughout the study period, whereas a significant decrease was observed for HoloTC from baseline to the 9th month.

The observed I-S and S-H relationships were not consistent and further conclusions cannot be extracted.

**Quality of included studies**

Table 3 summarizes the method used to assess the quality of the included studies. Only three studies had a high risk of bias<sup>(29,33,36)</sup>. Five studies had a moderate risk of bias<sup>(28,31,34,35,38)</sup> and eight studies reflect low risk of bias<sup>(30,32,37,39-43)</sup>. The most repeated reason for risk of bias across the studies was an inadequate explanation about the drop-outs and an inadequate assessment of exposure (method to assess vitamin B<sub>12</sub> intakes).

**Table 3** Assessment of methodological quality of included randomized controlled trials, longitudinal and cross-sectional studies

| Study  | Sequence generation adequate | Allocation concealment adequate | Blinding adequate | Drop-outs adequate and outcome data complete | Funder adequate | Lack of other potential threats to validity | Confounders | Assessment of exposure adequate | Overall risk of bias |
|--|------------------------------|---------------------------------|-------------------|--|-----------------|---|-------------|---------------------------------|----------------------|
| Dagnelle and van Stavoren (1994) <sup>(32)</sup>       | —                            | —                               | —                 | Unclear                                      | Yes             | Yes   | Yes         | Yes                             | Low                  |
| Worthington-White <i>et al.</i> (1994) <sup>(29)</sup> | Unclear                      | Yes                             | Yes               | Unclear                                      | Yes             | Unclear                                     | —           | —                               | High                 |
| Jones <i>et al.</i> (2007) <sup>(30)</sup>             | —                            | —                               | —                 | —  | Yes             | Yes   | Yes         | Yes                             | Low                  |
| Bjorke-Monsen <i>et al.</i> (2008) <sup>(28)</sup>     | Yes                          | Yes                             | Yes               | No   | Yes             | Yes   | —           | —                               | Moderate             |
| Hay <i>et al.</i> (2008) <sup>(31)</sup>               | —                            | —                               | —                 | Unclear                                      | Yes             | Yes   | No          | Yes                             | Moderate             |
| Papoutsakis <i>et al.</i> (2006) <sup>(33)</sup>       | —                            | —                               | —                 | —  | No              | Yes   | Yes         | No                              | High                 |
| Gewa <i>et al.</i> (2009) <sup>(36)</sup>              | Unclear                      | Unclear                         | No                | Unclear                                      | Yes             | —   | —           | —                               | High                 |
| Hay <i>et al.</i> (2011) <sup>(37)</sup>               | —                            | —                               | —                 | —  | Yes             | Yes   | Yes         | Yes                             | Low                  |
| Steluti <i>et al.</i> (2011) <sup>(34)</sup>           | —                            | —                               | —                 | —  | Yes             | Yes   | Yes         | No                              | Moderate             |
| Yeung <i>et al.</i> (2011) <sup>(35)</sup>             | —                            | —                               | —                 | —  | Yes             | Yes   | Yes         | No                              | Moderate             |
| Koebnick <i>et al.</i> (2002) <sup>(39)</sup>          | —                            | —                               | —                 | Unclear                                      | Yes             | Yes   | Yes         | Yes                             | Low                  |
| Lindblad <i>et al.</i> (2005) <sup>(40)</sup>          | —                            | —                               | —                 | Yes  | Yes             | Yes   | Yes         | Yes                             | Low                  |
| Muthayya <i>et al.</i> (2006) <sup>(42)</sup>          | —                            | —                               | —                 | Yes  | Yes             | Yes   | Yes         | Yes                             | Low                  |
| Morkbak <i>et al.</i> (2007) <sup>(41)</sup>           | —                            | —                               | —                 | Unclear                                      | Yes             | Yes   | Yes         | Yes                             | Low                  |
| Baker <i>et al.</i> (2009) <sup>(38)</sup>             | —                            | —                               | —                 | Unclear                                      | Yes             | No  | Yes         | Yes                             | Moderate             |
| Takimoto <i>et al.</i> (2011) <sup>(43)</sup>          | —                            | —                               | —                 | Yes  | Yes             | Yes   | Yes         | Yes                             | Low                  |

**Discussion**

From 5815 identified papers, only sixteen were suitable to be included in the review according to EURRECA’s eligibility criteria. From these, five papers focused only on descriptions of vitamin B<sub>12</sub> intakes and biomarkers without any stated association. Because of the small number of eligible papers included in the review, only a few main conclusions can be drawn for the specific population groups studied.

**Infants**

In this population group, vitamin B<sub>12</sub> (ingested or injected) was significantly and positively associated with vitamin B<sub>12</sub> biomarkers. Serum vitamin B<sub>12</sub> was investigated in all four studies. The evidence, however, was not sufficient for HoloTC (only one study<sup>(31)</sup>) or MMA (two studies<sup>(28,31)</sup>, while in one study<sup>(31)</sup>, associations were not found for MMA).

In this population group, the two included interventions were performed through injection of vitamin B<sub>12</sub>. Although injection could be a more reliable method of intervention, in general oral administration is better tolerated in the absence of neurological problems<sup>(44,45)</sup>. Moreover, it should be noted that exposure to vitamin B<sub>12</sub> via oral supplements or intramuscular injections is very different as e.g. bioavailability issues are different.

**Children and adolescents**

Among the four cross-sectional studies<sup>(33–35,37)</sup> included in this population group, the only available finding was the positive association between children’s intake of vitamin B<sub>12</sub> and serum HoloTC in one of them. In that study, serum vitamin B<sub>12</sub> and MMA were also investigated without any obtained association. The other three cross-sectional studies did not look for any association.

In the RCT of Gewa *et al.*<sup>(36)</sup>, it was demonstrated that higher vitamin B<sub>12</sub> intakes are associated with higher scores in one part of a cognitive test. However, only one study represents very limited data from which to extract a clear conclusion and in this respect, drawing conclusions may not be justified.

**Pregnant and lactating women**

Regarding the S-H relationships searched for in this group, as well as for I-S ones, no conclusions can be drawn due to the discrepancies in the results. One study<sup>(42)</sup> showed an association between status and fetal growth and three<sup>(38,40,43)</sup> showed no association. On the other hand, due to the heterogeneity shown in results regarding I-S relationships in all five included studies, it is possible to conclude that intake of vitamin B<sub>12</sub> in pregnant and lactating women is not related to vitamin B<sub>12</sub> concentration in their blood. This fact can be derived from the vitamin B<sub>12</sub> gradient in the placenta, between the fetus and the mother. During pregnancy, vitamin B<sub>12</sub> had been noted to decrease in mothers but not its transport

molecules. Such an observation of the placenta facilitating the transport of a critical nutrient (as occurs with vitamin B<sub>12</sub>) for fetal growth and development when the mother is deficient is another revelation of how important the placenta is in maintaining the development of the fetus<sup>(46,47)</sup>. In the other four studies<sup>(38–41)</sup> there were no significant or relevant associations present.

### ***Use of biomarkers in studies***

One of the currently open questions regarding vitamin B<sub>12</sub> is to determine the best biomarker to assess its status. In the present review, data were insufficient to draw conclusions about the effectiveness of serum HoloTC or MMA as a biomarker of vitamin B<sub>12</sub> status (only one study showed a positive association between vitamin B<sub>12</sub> intakes and HoloTC in children<sup>(37)</sup>). However, MMA and HoloTC are more sensitive markers for vitamin B<sub>12</sub> deficiency than plasma vitamin B<sub>12</sub><sup>(48)</sup> by reflecting sudden changes in vitamin B<sub>12</sub> homeostasis, whereas plasma vitamin B<sub>12</sub> seems to reflect the accumulation of vitamin B<sub>12</sub><sup>(49)</sup>. On the other hand, they are extremely variable in these periods of life, making difficult their interpretation<sup>(31)</sup>. Moreover, due to the ability of serum/plasma vitamin B<sub>12</sub> to describe the status of vitamin B<sub>12</sub> through time, without being influenced by punctual intake, serum/plasma vitamin B<sub>12</sub> is the most common biomarker to assess vitamin B<sub>12</sub> status.

### ***Cognitive function***

One of the constraints to the lack of data in the research on vitamin B<sub>12</sub> intake and cognitive function is that even detailed examinations are not sufficiently accurate to detect developmental delays in young infants. However, reports on short- and long-term neurological effects related to vitamin B<sub>12</sub> deficiency in young infants demonstrate the importance of an adequate vitamin B<sub>12</sub> status during the first months of life<sup>(28)</sup>. Vitamin B<sub>12</sub> is also suggested to be related with neurocognitive function in school-aged children<sup>(50)</sup>. In the present systematic review, two papers on this topic suggested this association (one in infants, the other in children). However, in the infants study<sup>(32)</sup>, the differences in scores in psychomotor tests were associated with type of diet (macrobiotic or omnivorous) and not with intake of vitamin B<sub>12</sub> (however, the authors found significant differences in vitamin B<sub>12</sub> intakes between diet groups).

### ***Megaloblastic anaemia***

Although being selected as a relevant health outcome for infants and children and adolescents, no paper on megaloblastic anaemia was finally included. However, some bibliography has reported megaloblastic anaemia as a typical symptom of vitamin B<sub>12</sub> deficiency, usually as a consequence of previous maternal vitamin B<sub>12</sub> deficiency<sup>(51)</sup>. Absence of included studies investigating this outcome suggests the low quality of reporting of the available studies, which were mostly old case reports.

No studies were found for megaloblastic anaemia in pregnant and lactating women. The explanation for no revealed hits could be that the literature about megaloblastic anaemia in this vulnerable group is linked mostly to intake and status of folate rather than the intake and status of vitamin B<sub>12</sub><sup>(52)</sup>.

### ***Growth***

Of four papers focusing on fetal/infant growth (SGA, IUGR or general growth) in pregnant and lactating women, as only one has shown a positive association, no clear conclusion can be extracted in this regard.

### ***Fetal malformations***

The literature reveals that neural tube defects are the most common fetal malformation linked to deficiency of vitamin B<sub>12</sub> in mothers<sup>(53)</sup>. However, due to the strict inclusion criteria of the present systematic review, no studies on this topic were included.

### ***Maternal pre-eclampsia***

This health outcome was mentioned in only one of the longitudinal studies in the pregnant and lactating women group. However, there was no significant difference in vitamin B<sub>12</sub> status among mothers who suffered pre-eclampsia compared with mothers without pre-eclampsia<sup>(40)</sup>. In another similar study, no significant differences were observed in both maternal and fetal serum vitamin B<sub>12</sub> between a severe pre-eclampsia group *v.* mild pre-eclampsia and control groups<sup>(54)</sup>.

### ***Conclusions***

The current systematic review emphasizes a number of knowledge gaps in the field of vitamin B<sub>12</sub> research for young populations and pregnant and lactating women, derived from the scarcity and the low quality of available studies.

One of the reasons for this scarce literature on vitamin B<sub>12</sub> in young population groups could be that mild vitamin B<sub>12</sub> deficiency is more prevalent among elderly people in association with a number of chronic diseases<sup>(55)</sup>.

There is also evidence that vitamin B<sub>12</sub> deficiency is uncommon in young populations, unless they belong to a vegan community, or live in a developing area, or have a congenital malabsorption syndrome<sup>(56)</sup>. However, the prevalence in younger groups may be higher than formerly recognized<sup>(57)</sup>.

RCT with enough power and varying doses of dietary intakes and duration of supplementation are required in order to establish vitamin B<sub>12</sub> recommendations for young populations. Further studies to correlate serum/plasma vitamin B<sub>12</sub>, MMA and HoloTC and also to explore vitamin B<sub>12</sub> adequacy in young age groups are needed.

## Acknowledgements

*Sources of funding:* The work reported herein has been carried out within the EURRECA Network of Excellence (www.eurreca.org) which is financially supported by the Commission of the European Communities, specific Research, Technology and Development (RTD) Programme 'Quality of Life and Management of Living Resources', within the Sixth Framework Programme, contract no. 036196. This report does not necessarily reflect the Commission's views or its future policy in this area. S.B.-S. was funded by a grant from the Aragon Regional Government (Diputación General de Aragón, DGA). *Conflicts of interest:* The authors declare no conflicts of interest. *Authors' contributions:* A.E.J.M.C., P.v.V., L.C.P.G.M.d.G. and L.A.M. designed and directed the study; I.I., R.A.M.D.-R., S.B.-S., E.L.D., M.N., V.B., M.H. and C.B. conducted the research; I.I. wrote the manuscript; R.A.M.D.-R. and L.A.M. participated in data interpretation; I.I. had responsibility for the final content. I.I., R.A.M.D.-R., S.B.-S., E.L.D., M.N., V.B., M.H., C.B., A.E.J.M.C., P.v.V., L.C.P.G.M.d.G. and L.A.M. critically reviewed the manuscript. All authors read and approved the final manuscript.

## References

- Roberts SB & McDonald R (1998) The evolution of a new research field: metabolic programming by early nutrition. *J Nutr* **128**, Suppl. 2, 400S.
- Hermoso M (2010) The nutritional requirements of infants. Towards EU alignment of reference values: the EURRECA network. *Matern Child Nutr* **6**, Suppl. 2, 55–83.
- Iglesia I (2010) Physiological and public health basis for assessing micronutrient requirements in children and adolescents. The EURRECA network. *Matern Child Nutr* **6**, Suppl. 2, 84–99.
- Hall Moran V, Lowe N, Crossland N *et al.* (2010) Nutritional requirements during lactation. Towards European alignment of reference values: the EURRECA network. *Matern Child Nutr* **6**, Suppl. 2, 39–54.
- Berti C, Decsi T, Dykes F *et al.* (2010) Critical issues in setting micronutrient recommendations for pregnant women: an insight. *Matern Child Nutr* **6**, Suppl. 2, 5–22.
- Doets EL, de Wit LS, Dhonukshe-Rutten RA *et al.* (2008) Current micronutrient recommendations in Europe: towards understanding their differences and similarities. *Eur J Nutr* **47**, Suppl. 1, 17–40.
- Serra-Majem L & Aranceta Bartrina J (2004) *Nutrición infantil y juvenil. Estudio enKid*. Barcelona: Masson.
- Tucker KL, Rich S, Rosenberg I *et al.* (2000) Plasma vitamin B-12 concentrations relate to intake source in the Framingham Offspring study. *Am J Clin Nutr* **71**, 514–522.
- Allen LH (2008) Causes of vitamin B<sub>12</sub> and folate deficiency. *Food Nutr Bull* **29**, Suppl. 2, S20–S34.
- Bor MV, Lydeking-Olsen E, Moller J *et al.* (2006) A daily intake of approximately 6 microg vitamin B-12 appears to saturate all the vitamin B-12-related variables in Danish postmenopausal women. *Am J Clin Nutr* **83**, 52–58.
- Vogiatzoglou A, Smith AD, Nurk E *et al.* (2009) Dietary sources of vitamin B-12 and their association with plasma vitamin B-12 concentrations in the general population: the Hordaland Homocysteine Study. *Am J Clin Nutr* **89**, 1078–1087.
- Kwan LL, Bermudez OI & Tucker KL (2002) Low vitamin B-12 intake and status are more prevalent in Hispanic older adults of Caribbean origin than in neighborhood-matched non-Hispanic whites. *J Nutr* **132**, 2059–2064.
- Dhonukshe-Rutten RA, Timotijevic L, Cavelaars AE *et al.* (2010) European micronutrient recommendations aligned: a general framework developed by EURRECA. *Eur J Clin Nutr* **64**, Suppl. 2, S2–S10.
- Ashwell M, Lambert JP, Alles MS *et al.* (2008) How we will produce the evidence-based EURRECA toolkit to support nutrition and food policy. *Eur J Nutr* **47**, Suppl. 1, 2–16.
- Atkinson SA & Koletzko B (2007) Determining life-stage groups and extrapolating nutrient intake values (NIVs). *Food Nutr Bull* **28**, Suppl. 1, S61–S76.
- King JC, Vorster HH & Tome DG (2007) Nutrient intake values (NIVs): a recommended terminology and framework for the derivation of values. *Food Nutr Bull* **28**, Suppl. 1, S16–S26.
- Cavelaars AE, Doets EL, Dhonukshe-Rutten RA *et al.* (2010) Prioritizing micronutrients for the purpose of reviewing their requirements: a protocol developed by EURRECA. *Eur J Clin Nutr* **64**, Suppl. 2, S19–S30.
- Dror DK & Allen LH (2008) Effect of vitamin B<sub>12</sub> deficiency on neurodevelopment in infants: current knowledge and possible mechanisms. *Nutr Rev* **66**, 250–255.
- Kuschel CA & Harding JE (2004) Multicomponent fortified human milk for promoting growth in preterm infants. *Cochrane Database Syst Rev* issue 1, CD000343.
- Mathews F (1996) Antioxidant nutrients in pregnancy: a systematic review of the literature. *Nutr Res Rev* **9**, 175–195.
- Molloy AM, Kirke PN, Brody LC *et al.* (2008) Effects of folate and vitamin B<sub>12</sub> deficiencies during pregnancy on fetal, infant, and child development. *Food Nutr Bull* **29**, Suppl. 2, S101–S111.
- Ramakrishnan U, Aburto N, McCabe G *et al.* (2004) Multimicronutrient interventions but not vitamin A or iron interventions alone improve child growth: results of 3 meta-analyses. *J Nutr* **134**, 2592–2602.
- Ray JG & Laskin CA (1999) Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. *Placenta* **20**, 519–529.
- Hoey L, Strain JJ & McNulty H (2009) Studies of biomarker responses to intervention with vitamin B-12: a systematic review of randomized controlled trials. *Am J Clin Nutr* **89**, issue 6, S1981–S1996.
- Fairweather-Tait SJ & Harvey LJ (2008) Micronutrient status methods: proceedings of the EURRECA workshop and working party on new approaches for measuring micronutrient status. *Br J Nutr* **99**, S1.
- Hooper L, Ashton K, Harvey LJ *et al.* (2009) Assessing potential biomarkers of micronutrient status by using a systematic review methodology: methods. *Am J Clin Nutr* **89**, issue 6, S1953–S1959.
- Higgins J & Green S (editors) (2011) *Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0*. The Cochrane Collaboration; available at www.cochrane-handbook.org
- Bjorke-Monsen AL, Torsvik I, Saetran H *et al.* (2008) Common metabolic profile in infants indicating impaired cobalamin status responds to cobalamin supplementation. *Pediatrics* **122**, 83–91.
- Worthington-White DA, Behnke M & Gross S (1994) Premature infants require additional folate and vitamin B-12 to reduce the severity of the anemia of prematurity. *Am J Clin Nutr* **60**, 930–935.
- Jones KM, Ramirez-Zea M, Zuleta C *et al.* (2007) Prevalent vitamin B-12 deficiency in twelve-month-old Guatemalan infants is predicted by maternal B-12 deficiency and infant diet. *J Nutr* **137**, 1307–1313.

31. Hay G, Johnston C, Whitelaw A *et al.* (2008) Folate and cobalamin status in relation to breastfeeding and weaning in healthy infants. *Am J Clin Nutr* **88**, 105–114.
32. Dagnelie PC & van Staveren WA (1994) Macrobiotic nutrition and child health: results of a population-based, mixed-longitudinal cohort study in The Netherlands. *Am J Clin Nutr* **59**, Suppl. 5, S1187–S1196.
33. Papoutsakis C, Yiannakouris N, Manios Y *et al.* (2006) The effect of MTHFR(C677T) genotype on plasma homocysteine concentrations in healthy children is influenced by gender. *Eur J Clin Nutr* **60**, 155–162.
34. Steluti J, Martini LA, Peters BS *et al.* (2011) Folate, vitamin B<sub>6</sub> and vitamin B<sub>12</sub> in adolescence: serum concentrations, prevalence of inadequate intakes and sources in food. *J Pediatr (Rio J)* **87**, 43–49.
35. Yeung LF, Cogswell ME, Carriquiry AL *et al.* (2011) Contributions of enriched cereal-grain products, ready-to-eat cereals, and supplements to folic acid and vitamin B-12 usual intake and folate and vitamin B-12 status in US children: National Health and Nutrition Examination Survey (NHANES), 2003–2006. *Am J Clin Nutr* **93**, 172–185.
36. Gewa CA, Weiss RE, Bwibo NO *et al.* (2009) Dietary micronutrients are associated with higher cognitive function gains among primary school children in rural Kenya. *Br J Nutr* **101**, 1378–1387.
37. Hay G, Trygg K, Whitelaw A *et al.* (2011) Folate and cobalamin status in relation to diet in healthy 2-y-old children. *Am J Clin Nutr* **93**, 727–735.
38. Baker PN, Wheeler SJ, Sanders TA *et al.* (2009) A prospective study of micronutrient status in adolescent pregnancy. *Am J Clin Nutr* **89**, 1114–1124.
39. Koebnick C, Heins UA, Dagnelie PC *et al.* (2002) Longitudinal concentrations of vitamin B(12) and vitamin B(12)-binding proteins during uncomplicated pregnancy. *Clin Chem* **48**, 928–933.
40. Lindblad B, Zaman S, Malik A *et al.* (2005) Folate, vitamin B<sub>12</sub>, and homocysteine levels in South Asian women with growth-retarded fetuses. *Acta Obstet Gynecol Scand* **84**, 1055–1061.
41. Morkbak AL, Ramlau-Hansen CH, Moller UK *et al.* (2007) A longitudinal study of serum cobalamins and its binding proteins in lactating women. *Eur J Clin Nutr* **61**, 184–189.
42. Muthayya S, Kurpad AV, Duggan CP *et al.* (2006) Low maternal vitamin B<sub>12</sub> status is associated with intrauterine growth retardation in urban South Indians. *Eur J Clin Nutr* **60**, 791–801.
43. Takimoto H, Hayashi F, Kusama K *et al.* (2011) Elevated maternal serum folate in the third trimester and reduced fetal growth: a longitudinal study. *J Nutr Sci Vitaminol (Tokyo)* **57**, 130–137.
44. Duyvendak M & Veldhuis GJ (2009) Oral better than parenteral supplementation of vitamin B<sub>12</sub>. *Ned Tijdschr Geneesk* **153**, B485.
45. Rufenacht P, Mach-Pascual S & Iten A (2008) Vitamin B<sub>12</sub> deficiency: a challenging diagnosis and treatment. *Rev Med Suisse* **4**, 2212–2214, 2216–2217.
46. Schneider H & Miller RK (2010) Receptor-mediated uptake and transport of macromolecules in the human placenta. *Int J Dev Biol* **54**, 367–375.
47. Molloy AM, Mills JL, McPartlin J *et al.* (2002) Maternal and fetal plasma homocysteine concentrations at birth: the influence of folate, vitamin B<sub>12</sub>, and the 5,10-methylenetetrahydrofolate reductase 677C→T variant. *Am J Obstet Gynecol* **186**, 499–503.
48. Hvas AM & Nexo E (2005) Holotranscobalamin – a first choice assay for diagnosing early vitamin B deficiency? *J Intern Med* **257**, 289–298.
49. Nexo E, Hvas AM, Bleie O *et al.* (2002) Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study. *Clin Chem* **48**, 1768–1771.
50. Villamor E, Mora-Plazas M, Forero Y *et al.* (2008) Vitamin B-12 status is associated with socioeconomic level and adherence to an animal food dietary pattern in Colombian school children. *J Nutr* **138**, 1391–1398.
51. Honzik T, Adamovicova M, Smolka V *et al.* (2010) Clinical presentation and metabolic consequences in 40 breastfed infants with nutritional vitamin B<sub>12</sub> deficiency – what have we learned? *Eur J Paediatr Neurol* **14**, 488–495.
52. Campbell BA (1995) Megaloblastic anemia in pregnancy. *Clin Obstet Gynecol* **38**, 455–462.
53. Ray JG & Blom HJ (2003) Vitamin B<sub>12</sub> insufficiency and the risk of fetal neural tube defects. *QJM* **96**, 289–295.
54. Acilmis YG, Dikensoy E, Kutlar AI *et al.* (2011) Homocysteine, folic acid and vitamin B<sub>12</sub> levels in maternal and umbilical cord plasma and homocysteine levels in placenta in pregnant women with pre-eclampsia. *J Obstet Gynaecol Res* **37**, 45–50.
55. Selhub J, Morris MS, Jacques PF *et al.* (2009) Folate–vitamin B-12 interaction in relation to cognitive impairment, anemia, and biochemical indicators of vitamin B-12 deficiency. *Am J Clin Nutr* **89**, issue 2, S702–S706.
56. Stabler SP & Allen RH (2004) Vitamin B<sub>12</sub> deficiency as a worldwide problem. *Annu Rev Nutr* **24**, 299–326.
57. Bjorke-Monsen AL & Ueland PM (2011) Cobalamin status in children. *J Inherit Metab Dis* **34**, 111–119.
58. Monsen AL, Refsum H, Markestad T *et al.* (2003) Cobalamin status and its biochemical markers methylmalonic acid and homocysteine in different age groups from 4 days to 19 years. *Clin Chem* **49**, 2067–2075.
59. Monsen AL, Schneede J & Ueland PM (2006) Mid-trimester amniotic fluid methionine concentrations: a predictor of birth weight and length. *Metabolism* **55**, 1186–1191.
60. Casanueva E, Viteri FE, Mares-Galindo M *et al.* (2006) Weekly iron as a safe alternative to daily supplementation for nonanemic pregnant women. *Arch Med Res* **37**, 674–682.
61. Choudhry VP, Saraya AK & Ghai OP (1972) Morphological changes in relation to haemopoietic nutrient deficiency in nutritional macrocytic anaemia in infancy and childhood. *Indian J Med Res* **60**, 1764–1773.
62. Cikot RJ, Steegers-Theunissen RP, Thomas CM *et al.* (2001) Longitudinal vitamin and homocysteine levels in normal pregnancy. *Br J Nutr* **85**, 49–58.
63. Couto FD, Moreira LM, Dos Santos DB *et al.* (2007) Folate, vitamin B<sub>12</sub> and total homocysteine levels in neonates from Brazil. *Eur J Clin Nutr* **61**, 382–386.
64. Cornel MC, de Smit DJ & de Jong-van den Berg LT (2005) Folic acid – the scientific debate as a base for public health policy. *Reprod Toxicol* **20**, 411–415.
65. Czeizel AE & Dudas I (1992) Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med* **327**, 1832–1835.
66. Czeizel AE & Medveczky E (2003) Periconceptional multi-vitamin supplementation and multimalformed offspring. *Obstet Gynecol* **102**, 1255–1261.
67. Dagnelie PC, van Staveren WA, Vergote FJ *et al.* (1989) Nutritional status of infants aged 4 to 18 months on macrobiotic diets and matched omnivorous control infants: a population-based mixed-longitudinal study. II. Growth and psychomotor development. *Eur J Clin Nutr* **43**, 325–338.
68. Dawson EB, Evans DR, Conway ME *et al.* (2000) Vitamin B<sub>12</sub> and folate bioavailability from two prenatal multivitamin/multimineral supplements. *Am J Perinatol* **17**, 193–199.
69. van Dusseldorp M, Schneede J, Refsum H *et al.* (1999) Risk of persistent cobalamin deficiency in adolescents fed a macrobiotic diet in early life. *Am J Clin Nutr* **69**, 664–671.
70. Eilander A, Muthayya S, van der Knaap H *et al.* (2010) Undernutrition, fatty acid and micronutrient status in relation to cognitive performance in Indian school children: a cross-sectional study. *Br J Nutr* **103**, 1056–1064.

71. Gomber S, Bhawna, Madan N *et al.* (2003) Prevalence & etiology of nutritional anaemia among school children of urban slums. *Indian J Med Res* **118**, 167–171.
72. Gomber S, Kumar S, Rusia U *et al.* (1998) Prevalence & etiology of nutritional anaemias in early childhood in an urban slum. *Indian J Med Res* **107**, 269–273.
73. Gordon BA & Carson RA (1976) Methylmalonic acidemia controlled with oral administration of vitamin B<sub>12</sub>. *CMAJ* **115**, 233–236.
74. Graham SM, Arvela OM & Wise GA (1992) Long-term neurologic consequences of nutritional vitamin B<sub>12</sub> deficiency in infants. *J Pediatr* **121**, 710–714.
75. Haggarty P, McCallum H, McBain H *et al.* (2006) Effect of B vitamins and genetics on success of *in-vitro* fertilisation: prospective cohort study. *Lancet* **367**, 1513–1519.
76. Haiden N, Klebermass K, Cardona F *et al.* (2006) A randomized, controlled trial of the effects of adding vitamin B<sub>12</sub> and folate to erythropoietin for the treatment of anemia of prematurity. *Pediatrics* **118**, 180–188.
77. Haiden N, Schwindt J, Cardona F *et al.* (2006) Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B<sub>12</sub> on the transfusion requirements of extremely low birth weight infants. *Pediatrics* **118**, 2004–2013.
78. Hay G, Clausen T, Whitelaw A *et al.* (2010) Maternal folate and cobalamin status predicts vitamin status in newborns and 6-month-old infants. *J Nutr* **140**, 557–564.
79. Hininger I, Favier M, Arnaud J *et al.* (2004) Effects of a combined micronutrient supplementation on maternal biological status and newborn anthropometrics measurements: a randomized double-blind, placebo-controlled trial in apparently healthy pregnant women. *Eur J Clin Nutr* **58**, 52–59.
80. Hjelt K & Krasilnikoff PA (1990) The impact of gluten on haematological status, dietary intakes of haemopoietic nutrients and vitamin B<sub>12</sub> and folic acid absorption in children with coeliac disease. *Acta Paediatr Scand* **79**, 911–919.
81. Huemer M, Simma B, Fowler B *et al.* (2005) Prenatal and postnatal treatment in cobalamin C defect. *J Pediatr* **147**, 469–472.
82. Järvenpää J, Schwab U, Lappalainen T *et al.* (2007) Fortified mineral water improves folate status and decreases plasma homocysteine concentration in pregnant women. *J Perinat Med* **35**, 108–114.
83. Johnson TE, Janes SJ, MacDonald A *et al.* (2002) An observational study to evaluate micronutrient status during enteral feeding. *Arch Dis Child* **86**, 411–415.
84. Knight EM, Spurlock BG, Edwards CH *et al.* (1994) Biochemical profile of African American women during three trimesters of pregnancy and at delivery. *J Nutr* **124**, Suppl. 6, S943–S953.
85. Levy R, Herzberg GR, Andrews WL *et al.* (1992) Thiamine, riboflavin, folate, and vitamin B<sub>12</sub> status of low birth weight infants receiving parenteral and enteral nutrition. *J Parenter Enter Nutr* **16**, 241–247.
86. López de Romaña G, Cusiramos S, López de Romaña D *et al.* (2005) Efficacy of multiple micronutrient supplementation for improving anemia, micronutrient status, growth, and morbidity of Peruvian infants. *J Nutr* **135**, issue 3, S646–S652.
87. Lovblad K, Ramelli G, Remonda L *et al.* (1997) Retardation of myelination due to dietary vitamin B<sub>12</sub> deficiency: cranial MRI findings. *Pediatr Radiol* **27**, 155–158.
88. Lundgren J & Blennow G (1999) Vitamin B<sub>12</sub> deficiency may cause benign familial infantile convulsions: a case report. *Acta Paediatr* **88**, 1158–1160.
89. Makedos G, Papanicolaou A, Hitoglou A *et al.* (2007) Homocysteine, folic acid and B<sub>12</sub> serum levels in pregnancy complicated with preeclampsia. *Arch Gynecol Obstet* **275**, 121–124.
90. Mamluk RJ, Isenberg JN, Rassin DK *et al.* (1986) A cobalamin metabolic defect with homocystinuria, methylmalonic aciduria and macrocytic anemia. *Neuropediatrics* **17**, 94–99.
91. Martin I, Gibert MJ, Pintos C *et al.* (2004) Oxidative stress in mothers who have conceived fetus with neural tube defects: the role of amino thiols and selenium. *Clin Nutr* **23**, 507–514.
92. Mathan VI, Baker SJ, Sood SK *et al.* (1979) WHO sponsored collaborative studies on nutritional anaemia in India. The effects of ascorbic acid and protein supplementation on the response of pregnant women to iron, pteroylglutamic acid and cyanocobalamin therapy. *Br J Nutr* **42**, 391–398.
93. Maurage C, Dalloul C, Moussa F *et al.* (1995) Efficacy of oral administration of a micellar solution of vitamin K during the neonatal period. *Arch Pediatr* **2**, 328–332.
94. Masalha R, Afawi Z, Mahajnah M *et al.* (2008) The impact of nutritional vitamin B<sub>12</sub>, folate and hemoglobin deficiency on school performance of elementary school children. *J Pediatr Neurol* **6**, 243–248.
95. McCoy H, Kenney MA, Kirby A *et al.* (1984) Nutrient intakes of female adolescents from eight southern states. *J Am Diet Assoc* **84**, 1453–1460.
96. McGrath N, Bellinger D, Robins J *et al.* (2006) Effect of maternal multivitamin supplementation on the mental and psychomotor development of children who are born to HIV-1-infected mothers in Tanzania. *Pediatrics* **117**, e216–e225.
97. McNulty H, Eaton-Evans J, Cran G *et al.* (1996) Nutrient intakes and impact of fortified breakfast cereals in schoolchildren. *Arch Dis Child* **75**, 474–481.
98. Mena PN, Pittaluga EP, Blanco A *et al.* (2001) B<sub>12</sub> vitamin does not change the evolution of the anemia in preterm babies. *Rev Chil Pediatr* **72**, 34–39.
99. Merialdi M, Caulfield LE, Zavaleta N *et al.* (2004) Randomized, controlled trial of prenatal zinc supplementation and fetal bone growth. *Am J Clin Nutr* **79**, 826–830.
100. Metcalf R, Dilena B, Gibson R *et al.* (1994) How appropriate are commercially available human milk fortifiers? *J Paediatr Child Health* **30**, 350–355.
101. Metz J, Festenstein H & Welch P (1965) Effect of folic acid and vitamin B<sub>12</sub> supplementation on tests of folate and vitamin B<sub>12</sub> nutrition in pregnancy. *Am J Clin Nutr* **16**, 472–479.
102. Mills EJ, Wu P, Seely D *et al.* (2005) Vitamin supplementation for prevention of mother-to-child transmission of HIV and pre-term delivery: a systematic review of randomized trial including more than 2800 women. *AIDS Res Ther* **2**, 4.
103. Minet JC, Bisse E, Aebischer CP *et al.* (2000) Assessment of vitamin B-12, folate, and vitamin B-6 status and relation to sulfur amino acid metabolism in neonates. *Am J Clin Nutr* **72**, 751–757.
104. Miyake Y, Sasaki S, Tanaka K *et al.* (2006) Dietary folate and vitamins B<sub>12</sub>, B<sub>6</sub>, and B<sub>2</sub> intake and the risk of postpartum depression in Japan: the Osaka Maternal and Child Health Study. *J Affect Disord* **96**, 133–138.
105. Molloy AM, Kirke P, Hillary I *et al.* (1985) Maternal serum folate and vitamin B<sub>12</sub> concentrations in pregnancies associated with neural tube defects. *Arch Dis Child* **60**, 660–665.
106. Molloy AM, Mills JL, Cox C *et al.* (2005) Choline and homocysteine interrelations in umbilical cord and maternal plasma at delivery. *Am J Clin Nutr* **82**, 836–842.
107. Monagle PT & Tauro GP (1997) Infantile megaloblastosis secondary to maternal vitamin B<sub>12</sub> deficiency. *Clin Lab Haematol* **19**, 23–25.
108. Moran VH (2007) Nutritional status in pregnant adolescents: a systematic review of biochemical markers. *Matern Child Nutr* **3**, 74–93.



109. Morkbak AL, Hvas AM, Milman N *et al.* (2007) Holotranscobalamin remains unchanged during pregnancy. Longitudinal changes of cobalamins and their binding proteins during pregnancy and postpartum. *Haematologica* **92**, 1711–1712.
110. Msolla MJ & Kinabo JL (1997) Prevalence of anaemia in pregnant women during the last trimester. *Int J Food Sci Nutr* **48**, 265–270.
111. Murphy MM, Molloy AM, Ueland PM *et al.* (2007) Longitudinal study of the effect of pregnancy on maternal and fetal cobalamin status in healthy women and their offspring. *J Nutr* **137**, 1863–1867.
112. Mwanda OW & Dave P (1999) Megaloblastic marrow in macrocytic anaemias at Kenyatta National and M P Shah Hospitals, Nairobi. *East Afr Med J* **76**, 610–614.
113. Neiger R, Wise C, Contag SA *et al.* (1993) First trimester bleeding and pregnancy outcome in gravidas with normal and low folate levels. *Am J Perinatol* **10**, 460–462.
114. Nelen WL, Blom HJ, Steegers EA *et al.* (2000) Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. *Obstet Gynecol* **95**, 519–524.
115. Neri I, Allais G, Schiapparelli P *et al.* (2005) Acupuncture versus pharmacological approach to reduce hyperemesis gravidarum discomfort. *Minerva Ginecol* **57**, 471–475.
116. Neuhouser ML, Beresford SA, Hickok DE *et al.* (1998) Absorption of dietary and supplemental folate in women with prior pregnancies with neural tube defects and controls. *J Am Coll Nutr* **17**, 625–630.
117. Neumann CG & Harrison GG (1994) Onset and evolution of stunting in infants and children. Examples from the Human Nutrition Collaborative Research Support Program. Kenya and Egypt studies. *Eur J Clin Nutr* **48**, Suppl.1, S90–S102.
118. Niebyl JR & Goodwin TM (2002) Overview of nausea and vomiting of pregnancy with an emphasis on vitamins and ginger. *Am J Obstet Gynecol* **186**, Suppl. 5, S253–S255.
119. Nikolaus E & Nikolaus K (1979) Effect of a mixture of cyanocobalamin, glutamine and phosphoserine on performance and behavior of schoolchildren. *Therapiewoche* **29**, 7353–7359.
120. Osganian SK, Stampfer MJ, Spiegelman D *et al.* (1999) Distribution of and factors associated with serum homocysteine levels in children: Child and Adolescent Trial for Cardiovascular Health. *JAMA* **281**, 1189–1196.
121. Patel KD & Lovelady CA (1998) Vitamin B<sub>12</sub> status of east Indian vegetarian lactating women living in the United States. *Nutr Res* **18**, 1839–1846.
122. Ratan SK, Rattan KN, Pandey RM *et al.* (2008) Evaluation of the levels of folate, vitamin B<sub>12</sub>, homocysteine and fluoride in the parents and the affected neonates with neural tube defect and their matched controls. *Pediatr Surg Int* **24**, 803–808.
123. Ronnenberg AG, Goldman MB, Aitken IW *et al.* (2000) Anemia and deficiencies of folate and vitamin B-6 are common and vary with season in Chinese women of childbearing age. *J Nutr* **130**, 2703–2710.
124. Ronnenberg AG, Goldman MB, Chen D *et al.* (2002) Preconception homocysteine and B vitamin status and birth outcomes in Chinese women. *Am J Clin Nutr* **76**, 1385–1391.
125. Ronnenberg AG, Goldman MB, Chen D *et al.* (2002) Preconception folate and vitamin B(6) status and clinical spontaneous abortion in Chinese women. *Obstet Gynecol* **100**, 107–113.
126. Ronnenberg AG, Venners SA, Xu X *et al.* (2007) Preconception B-vitamin and homocysteine status, conception, and early pregnancy loss. *Am J Epidemiol* **166**, 304–312.
127. Rumbold A, Middleton P & Crowther CA (2005) Vitamin supplementation for preventing miscarriage. *Cochrane Database Syst Rev* issue 2, CD004073.
128. Sachdeva R & Mann SK (1994) Impact of nutrition counselling and supplements on the mineral nutriture of rural pregnant women and their neonates. *Indian Pediatr* **31**, 643–649.
129. Scatliff CE, Koski KG & Scott ME (2011) Diarrhea and novel dietary factors emerge as predictors of serum vitamin B<sub>12</sub> in Panamanian children. *Food Nutr Bull* **32**, 54–59.
130. Schneede J, Dagnelie PC, van Staveren WA *et al.* (1994) Methylmalonic acid and homocysteine in plasma as indicators of functional cobalamin deficiency in infants on macrobiotic diets. *Pediatr Res* **36**, 194–201.
131. Shih VE, Coulombe JT, Maties M *et al.* (1976) Methylmalonic aciduria in the newborn. *N Engl J Med* **295**, 1320–1321.
132. Siekmann JH, Allen LH, Bwibo NO *et al.* (2003) Kenyan school children have multiple micronutrient deficiencies, but increased plasma vitamin B-12 is the only detectable micronutrient response to meat or milk supplementation. *J Nutr* **133**, 11 Suppl. 2, 3972S–3980S.
133. Singla PN, Gupta HP, Ahuja C *et al.* (1982) Deficiency anaemias in preschool children – estimation of prevalence based on response to haematinic supplementation. *J Trop Pediatr* **28**, 77–80.
134. Sivakumar B, Nair KM, Sreeramulu D *et al.* (2006) Effect of micronutrient supplement on health and nutritional status of schoolchildren: biochemical status. *Nutrition* **22**, 1 Suppl., S15–S25.
135. Smith Fawzi MC, Kaaya SF, Mbwambo J *et al.* (2007) Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of life in a resource-poor setting. *HIV Med* **8**, 203–212.
136. Sneed SM, Zane C & Thomas MR (1981) The effects of ascorbic acid, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, and folic acid supplementation on the breast milk and maternal nutritional status of low socioeconomic lactating women. *Am J Clin Nutr* **34**, 1338–1346.
137. Sohrabvand F, Shariat M & Haghollahi F (2006) Vitamin B supplementation for leg cramps during pregnancy. *Int J Gynaecol Obstet* **95**, 48–49.
138. Steegers-Theunissen RP, Boers GH, Blom HJ *et al.* (1995) Neural tube defects and elevated homocysteine levels in amniotic fluid. *Am J Obstet Gynecol* **172**, 1436–1441.
139. Steen MT, Boddie AM, Fisher AJ *et al.* (1998) Neural-tube defects are associated with low concentrations of cobalamin (vitamin B<sub>12</sub>) in amniotic fluid. *Prenat Diagn* **18**, 545–555.
140. Strand TA, Taneja S, Bhandari N *et al.* (2007) Folate, but not vitamin B-12 status, predicts respiratory morbidity in north Indian children. *Am J Clin Nutr* **86**, 139–144.
141. Suarez L, Hendricks K, Felkner M *et al.* (2003) Maternal serum B<sub>12</sub> levels and risk for neural tube defects in a Texas–Mexico border population. *Ann Epidemiol* **13**, 81–88.
142. Thomas NE, Cooper SM, Baker JS *et al.* (2008) Homocyst(e)ine, folate, and vitamin B<sub>12</sub> status in a cohort of Welsh young people aged 12–13 years old. *Res Sports Med* **16**, 233–243.
143. Thompson MD, Cole DE & Ray JG (2009) Vitamin B-12 and neural tube defects: the Canadian experience. *Am J Clin Nutr* **89**, issue 2, S697–S701.
144. Thoradeniya T, Wickremasinghe R, Ramanayake R *et al.* (2006) Low folic acid status and its association with anaemia in urban adolescent girls and women of child-bearing age in Sri Lanka. *Br J Nutr* **95**, 511–516.
145. Thurlow RA, Winichagoon P, Green T *et al.* (2005) Only a small proportion of anemia in northeast Thai schoolchildren is associated with iron deficiency. *Am J Clin Nutr* **82**, 380–387.

146. Valman HB (1972) Late vitamin B<sub>12</sub> deficiency following resection of the ileum in the neonatal period. *Acta Paediatr Scand* **61**, 561–564.
147. Veena SR, Krishnaveni GV, Srinivasan K *et al.* (2010) Higher maternal plasma folate but not vitamin B-12 concentrations during pregnancy are associated with better cognitive function scores in 9- to 10-year-old children in South India. *J Nutr* **140**, 1014–1022.
148. Verkleij-Hagoort AC, van Driel LM, Lindemans J *et al.* (2008) Genetic and lifestyle factors related to the periconception vitamin B<sub>12</sub> status and congenital heart defects: a Dutch case–control study. *Mol Genet Metab* **94**, 112–119.
149. Villamor E, Mora-Plazas M, Forero Y *et al.* (2008) Vitamin B-12 status is associated with socioeconomic level and adherence to an animal food dietary pattern in Colombian school children. *J Nutr* **138**, 1391–1398.
150. Vinod Kumar M & Rajagopalan S (2008) Trial using multiple micronutrient food supplement and its effect on cognition. *Indian J Pediatr* **75**, 671–678.
151. Vujkovic M, Ocke MC, van der Spek PJ *et al.* (2007) Maternal Western dietary patterns and the risk of developing a cleft lip with or without a cleft palate. *Obstet Gynecol* **110**, 378–384.
152. Vujkovic M, Steegers EA, Looman CW *et al.* (2009) The maternal Mediterranean dietary pattern is associated with a reduced risk of spina bifida in the offspring. *BJOG* **116**, 408–415.
153. Wald NJ, Hackshaw AD, Stone R *et al.* (1996) Blood folic acid and vitamin B<sub>12</sub> in relation to neural tube defects. *Br J Obstet Gynaecol* **103**, 319–324.
154. Wright ME (1995) A case–control study of maternal nutrition and neural tube defects in Northern Ireland. *Midwifery* **11**, 146–152.